Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.1 USD | -1.22% | -0.40% | -40.42% |
Jun. 03 | Oppenheimer Adjusts Immunovant Price Target to $46 From $50, Maintains Outperform Rating | MT |
May. 30 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
Business Summary
Number of employees: 207
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 19-05-31 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 21-10-03 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ian Gourley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Maria Alba
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jennifer Moseley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-08-23 |
Jay Stout
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-03-31 |
Chief Tech/Sci/R&D Officer | 66 | 21-05-31 | |
Chau Cheng
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 19-12-17 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 19-12-17 |
Douglas Hughes
BRD | Director/Board Member | 62 | 19-12-17 |
Atul Pande
BRD | Director/Board Member | 69 | 19-12-17 |
Frank Torti
CHM | Chairman | 45 | 19-12-17 |
Eric Venker
BRD | Director/Board Member | 37 | 20-02-17 |
Peter Salzmann
CEO | Chief Executive Officer | 56 | 19-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 146,053,941 | 62,422,461 ( 42.74 %) | 0 | 42.74 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.42% | 3.71B | |
+49.21% | 56.95B | |
+39.98% | 40.26B | |
-6.86% | 39.32B | |
-4.42% | 28.37B | |
+12.00% | 26.45B | |
-18.27% | 19.41B | |
+29.57% | 12.54B | |
+25.41% | 12.21B | |
-0.35% | 12.15B |
- Stock Market
- Equities
- IMVT Stock
- Company Immunovant, Inc.